Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Long Term Study of the Impact of Quantitative Molecular Monitoring of Bcr-Abl Transcripts on the Risk of Relapse of CML After Allogeneic HSCT.

Mario Arpinati, MD, PhD, Marilina Amabile, maria Teresa Bochicchio, Angela Poerio, Giuseppe Bandini, Francesca Bonifazi, MD, Marta Stanzani, MD, PhD, Fausto Castagnetti, Gianantonio Rosti, Giovanni Martinelli, Michele Baccarani, MD

Blood (2010) 116 (21): 1287.

https://doi.org/10.1182/blood.V116.21.1287.1287

Published: 2010

Journal Articles

Low-Level Bcr-Abl Kinase Domain Mutations Are Very Rare In Chronic Myeloid Leukemia Patients Who Are In Major Molecular Response After 12 Months of First-Line Nilotinib Therapy.

Simona Soverini, PhD, Angela Poerio, Caterina Debenedittis, Ilaria Iacobucci, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Francesca Palandri, Gabriele Gugliotta, Marilina Amabile, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli, MD

Blood (2010) 116 (21): 1666.

https://doi.org/10.1182/blood.V116.21.1666.1666

Published: 2010

Journal Articles

Evaluation of the GeneXpert Assay for the Monitoring of BCR-ABL Transcript Levels In Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of a Comparison with the Manual and Traditional Manual TaqMan RQ-PCR Assay

Marco Suriano, Giovanni Martinelli, Angela Poerio, Marilina Amabile, Gianantonio Rosti, Fausto Castagnetti, Ilaria Iacobucci, Simona Soverini, Annalisa Lonetti, Cristina Papayannidis, Mariachiara Abbenante, Sarah Parisi, Francesca Palandri, Michele Baccarani, MD

Blood (2010) 116 (21): 4831.

https://doi.org/10.1182/blood.V116.21.4831.4831

Published: 2010

Journal Articles

Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression

Simona Soverini, Angela Poerio, Alberto Ferrarini, Ilaria Iacobucci, Marco Sazzini, Joannah Score, PhD, Enrico Giacomelli, Luciano Xumerle, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Francesca Palandri, Gabriele Gugliotta, Marilina Amabile, Gianantonio Rosti, Michele Baccarani, Nicholas C. P. Cross, MD, Massimo Delledonne, Giovanni Martinelli

Blood (2010) 116 (21): 885.

https://doi.org/10.1182/blood.V116.21.885.885

Published: 2010

Journal Articles

First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, “Deep” and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party

Blood (2010) 116 (21): 2720.

https://doi.org/10.1182/blood.V116.21.2720.2720

Published: 2010

Journal Articles

Nilotinib for the frontline treatment of Ph + chronic myeloid leukemia

Blood (2009) 114 (24): 4933–4938.

https://doi.org/10.1182/blood-2009-07-232595

Published: 2009

Journal Articles

CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.

Carolina Terragna, Sandra Durante, Annalisa Astolfi, Francesca Palandri, Fausto Castagnetti, Gianantonio Rosti, Nicoletta Testoni, Simona Luatti, Ilaria Iacobucci, PhD, Thea Kalebic, MD, Simona Soverini, Marilina Amabile, Angela Poerio, Michele Baccarani, Giovanni Martinelli

Blood (2009) 114 (22): 2174.

https://doi.org/10.1182/blood.V114.22.2174.2174

Published: 2009

Journal Articles

High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes.

Simona Soverini, PhD, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Annalisa Astolfi, Serena Formica, Francesca Palandri, Ilaria Iacobucci, Gabriele Gugliotta, Angela Poerio, Marilina Amabile, Giulia Marzocchi, Nicoletta Testoni, Elisabetta Abruzzese, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli

Blood (2009) 114 (22): 2176.

https://doi.org/10.1182/blood.V114.22.2176.2176

Published: 2009

Journal Articles

High-Resolution Genome Wide Copy Number Alteration (CNA) and Loss of Heterozigosity (LOH) Analysis in Chronic Myeloid Leukemia (CML) Shows That High and Intermediate Sokal Risk Pts (Pts) Have Multiple Losses Targeting Genes Involved in DNA Repair.

Simona Soverini, PhD, Sabrina Colarossi, Alessandra Gnani, Annalisa Astolfi, Serena Formica, Fausto Castagnetti, Francesca Palandri, Gabriele Gugliotta, Angela Poerio, Ilaria Iacobucci, Marilina Amabile, Giulia Marzocchi, Simona Luatti, Carolina Terragna, Sandra Durante, Nicoletta Testoni, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli

Blood (2009) 114 (22): 3262.

https://doi.org/10.1182/blood.V114.22.3262.3262

Published: 2009

Journal Articles

Whole-Transcriptome Sequencing of a Chronic Myeloid Leukemia (CML) Patient at Diagnosis and at the Time of Progression to Blast Crisis (BC).

Blood (2009) 114 (22): 4259.

https://doi.org/10.1182/blood.V114.22.4259.4259

Published: 2009

Journal Articles

The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.

Francesca Palandri, Fausto Castagnetti, Ilaria Iacobucci, Marilina Amabile, Gabriele Gugliotta, Angela Poerio, Massimo Breccia, Enrico Gottardi, Bruno Martino, Ivana Pierri, Fabrizio Quarantelli, Franca Radaelli, Giorgina Specchia, Fabrizio Pane, Giuseppe Saglio, Giovanni Martinelli, Gianantonio Rosti, Michele Baccarani

Blood (2009) 114 (22): 2192.

https://doi.org/10.1182/blood.V114.22.2192.2192

Published: 2009

Journal Articles

Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience.

Blood (2009) 114 (22): 2027.

https://doi.org/10.1182/blood.V114.22.2027.2027

Published: 2009

Journal Articles

Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.

Blood (2009) 114 (22): 2205.

https://doi.org/10.1182/blood.V114.22.2205.2205

Published: 2009

Journal Articles

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

Blood (2009) 114 (10): 2168–2171.

https://doi.org/10.1182/blood-2009-01-197186

Published: 2009

Includes: Supplemental data

Journal Articles

High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party

Blood (2008) 112 (11): 181.

https://doi.org/10.1182/blood.V112.11.181.181

Published: 2008

Journal Articles

Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score

Carolina Terragna, Sandra Durante, Annalisa Astolfi, Francesca Palandri, Fausto Castagnetti, Nicoletta Testoni, Simona Luatti, Gianantonio Rosti, Marilina Amabile, Angela Poerio, Ilaria Iacobucci, Simona Soverini, Thea Kalebic, MD, Michele Baccarani, Giovanni Martinelli

Blood (2008) 112 (11): 3190.

https://doi.org/10.1182/blood.V112.11.3190.3190

Published: 2008

Journal Articles

Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.

Blood (2008) 112 (11): 2118.

https://doi.org/10.1182/blood.V112.11.2118.2118

Published: 2008

Journal Articles

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance

Blood (2008) 112 (9): 3847–3855.

https://doi.org/10.1182/blood-2007-09-112631

Published: 2008

Includes: Supplemental data

Journal Articles

In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations.

Simona Soverini, Alessandra Gnani, Sabrina Colarossi, Fausto Castagnetti, Elisabetta Abruzzese, Serena Merante, Massimo Breccia, Adele Capucci, Giorgina Specchia, Franca Radaelli, Francesca Palandri, Angela Poerio, Ilaria Iacobucci, Marilina Amabile, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli

Blood (2007) 110 (11): 1934.

https://doi.org/10.1182/blood.V110.11.1934.1934

Published: 2007

Journal Articles

Philadelphia Chromosome-Positive Leukemia Patients Who Harbor Imatinib-Resistant Mutations Have a Higher Likelihood of Developing Additional Mutations Associated with Resistance to Novel Tyrosine Kinase Inhibitors.

Simona Soverini, Alessandra Gnani, Sabrina Colarossi, Fausto Castagnetti, Francesca Palandri, Panagiota Giannoulia, Stefania Paolini, Elisabetta Abruzzese, Serena Merante, Michela Rondoni, Ilaria Iacobucci, Angela Poerio, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli

Blood (2007) 110 (11): 322.

https://doi.org/10.1182/blood.V110.11.322.322

Published: 2007

NARROW

Long Term Study of the Impact of Quantitative Molecular Monitoring of Bcr-Abl Transcripts on the Risk of Relapse of CML After Allogeneic HSCT.

Low-Level Bcr-Abl Kinase Domain Mutations Are Very Rare In Chronic Myeloid Leukemia Patients Who Are In Major Molecular Response After 12 Months of First-Line Nilotinib Therapy.

Evaluation of the GeneXpert Assay for the Monitoring of BCR-ABL Transcript Levels In Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of a Comparison with the Manual and Traditional Manual TaqMan RQ-PCR Assay

Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression

Nilotinib for the frontline treatment of Ph + chronic myeloid leukemia

CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.

High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes.

High-Resolution Genome Wide Copy Number Alteration (CNA) and Loss of Heterozigosity (LOH) Analysis in Chronic Myeloid Leukemia (CML) Shows That High and Intermediate Sokal Risk Pts (Pts) Have Multiple Losses Targeting Genes Involved in DNA Repair.

Whole-Transcriptome Sequencing of a Chronic Myeloid Leukemia (CML) Patient at Diagnosis and at the Time of Progression to Blast Crisis (BC).

The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.

Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience.

Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party

Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score

Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance

In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations.

Philadelphia Chromosome-Positive Leukemia Patients Who Harbor Imatinib-Resistant Mutations Have a Higher Likelihood of Developing Additional Mutations Associated with Resistance to Novel Tyrosine Kinase Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only